The missing sinks: slip localization in faults, damage zones, and the seismic energy budget

No abstract available

F.A.R.M. Phase One

Non-Peer ReviewedF.A.R.M. Phase one is a computer program which controls the processing of soil samples at Plains Innovative Laboratory Services in Saskatoon. This video describes the four steps of the soil testing process and shows how this computer program maintains control of the sample flow through the laboratory and maintains the integrity of the data in the system. The video follows the soil samples through the various analytical procedures up to the printing of the final report which is faxed and mailed to the fertilizer dealer or farmer. The showing of this video will demonstrate the procedures involved in the analysis of a soil sample and outline the quality assurance procedures that are part of the system

A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3-4 weeks, the aim of the current study was to establish the anti-tumour and bone effects of a single administration of doxorubicin/zoledronic acid combination therapy in a bone metastasis model. MDA-MB-231-GFP cells were injected i.c. in 6-week-old nude mice. On day 2, animals received PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 μg/kg s.c.) or doxorubicin followed 24 h later by zoledronic acid. Anti-tumour effects were assessed on days 15/23 by quantification of apoptotic and proliferating cells and changes in expression of genes implicated in apoptosis, proliferation and bone turnover. Bone effects were assessed by μCT analysis, bone histomorphometry and measurement of serum markers. A tumour-free control group was included. Combination treatment reduced bone tumour burden compared to single agent or PBS control and increased levels of tumour cell apoptosis on day 15, but this was no longer detectable on day 23. Animals receiving zoledronic acid had increased bone density, without evidence of tumour-induced lesions. Bone histomorphometry showed that zoledronic acid caused a decrease in osteoblast and osteoclast numbers and an increase in osteoclast size, in both tumour-free and tumour-bearing animals. Our data show that although zoledronic acid modifies the bone microenvironment through effects on both osteoblasts and osteoclasts, this does not result in a significant anti-tumour effect in the absence of doxorubicin. © 2012 Elsevier GmbH. All rights reserved

Fluid-membrane tethers: minimal surfaces and elastic boundary layers

Thin cylindrical tethers are common lipid bilayer membrane structures, arising in situations ranging from micromanipulation experiments on artificial vesicles to the dynamic structure of the Golgi apparatus. We study the shape and formation of a tether in terms of the classical soap-film problem, which is applied to the case of a membrane disk under tension subject to a point force. A tether forms from the elastic boundary layer near the point of application of the force, for sufficiently large displacement. Analytic results for various aspects of the membrane shape are given.Comment: 12 page

Spectral Measures and Generating Series for Nimrep Graphs in Subfactor Theory II: SU(3)

We complete the computation of spectral measures for SU(3) nimrep graphs arising in subfactor theory, namely the SU(3) ADE graphs associated with SU(3) modular invariants and the McKay graphs of finite subgroups of SU(3). For the SU(2) graphs the spectral measures distill onto very special subsets of the semicircle/circle, whilst for the SU(3) graphs the spectral measures distill onto very special subsets of the discoid/torus. The theory of nimreps allows us to compute these measures precisely. We have previously determined spectral measures for some nimrep graphs arising in subfactor theory, particularly those associated with all SU(2) modular invariants, all subgroups of SU(2), the torus, SU(3), and some SU(3) graphs.Comment: 38 pages, 21 figure

On an Asymptotic Series of Ramanujan

An asymptotic series in Ramanujan's second notebook (Entry 10, Chapter 3) is concerned with the behavior of the expected value of $\phi(X)$ for large $\lambda$ where $X$ is a Poisson random variable with mean $\lambda$ and $\phi$ is a function satisfying certain growth conditions. We generalize this by studying the asymptotics of the expected value of $\phi(X)$ when the distribution of $X$ belongs to a suitable family indexed by a convolution parameter. Examples include the problem of inverse moments for distribution families such as the binomial or the negative binomial.Comment: To appear, Ramanujan

The Nakayama automorphism of the almost Calabi-Yau algebras associated to SU(3) modular invariants

We determine the Nakayama automorphism of the almost Calabi-Yau algebra A associated to the braided subfactors or nimrep graphs associated to each SU(3) modular invariant. We use this to determine a resolution of A as an A-A bimodule, which will yield a projective resolution of A.Comment: 46 pages which constitutes the published version, plus an Appendix detailing some long calculations. arXiv admin note: text overlap with arXiv:1110.454

Problems and possibilities in fine-tuning of the Cepheid P-L relationship

Factors contributing to the scatter around the ridge-line period-luminosity relationship are listed, followed by a discussion how to eliminate the adverse effects of these factors (mode of pulsation, crossing number, temperature range, reddening, binarity, metallicity, non-linearity of the relationship, blending), in order to reduce the dispersion of the P-L relationship.Comment: 7 pages, 8 figures; accepted for publication in Astrophysics & Space Scienc

NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease

Animal models of multiple myeloma vary in terms of consistency of onset, degree of tumour burden and degree of myeloma bone disease. Here we describe five pre-clinical models of myeloma in NOD/SCID-GAMMA mice to specifically study the effects of therapeutic agents on myeloma bone disease. Groups of 7–8 week old female irradiated NOD/SCID-GAMMA mice were injected intravenously via the tail vein with either 1x106 JJN3, U266, XG-1 or OPM-2 human myeloma cell lines or patient-derived myeloma cells. At the first signs of morbidity in each tumour group all animals were sacrificed. Tumour load was measured by histological analysis, and bone disease was assessed by micro-CT and standard histomorphometric methods. Mice injected with JJN3, U266 or OPM-2 cells showed high tumour bone marrow infiltration of the long bones with low variability, resulting in osteolytic lesions. In contrast, mice injected with XG-1 or patient-derived myeloma cells showed lower tumour bone marrow infiltration and less bone disease with high variability. Injection of JJN3 cells into NOD/SCID-GAMMA mice resulted in an aggressive, short-term model of myeloma with mice exhibiting signs of morbidity 3 weeks later. Treating these mice with zoledronic acid at the time of tumour cell injection or once tumour was established prevented JJN3-induced bone disease but did not reduce tumour burden, whereas, carfilzomib treatment given once tumour was established significantly reduced tumour burden. Injection of U266, XG-1, OPM-2 and patient-derived myeloma cells resulted in less aggressive longer-term models of myeloma with mice exhibiting signs of morbidity 8 weeks later. Treating U266-induced disease with zoledronic acid prevented the formation of osteolytic lesions and trabecular bone loss as well as reducing tumour burden whereas, carfilzomib treatment only reduced tumour burden. In summary, JJN3, U266 or OPM-2 cells injected into NOD/SCID-GAMMA mice provide robust models to study anti-myeloma therapies, particularly those targeting myeloma bone disease

Ab initio calculation of the neutron-proton mass difference

The existence and stability of atoms rely on the fact that neutrons are more massive than protons. The measured mass difference is only 0.14\% of the average of the two masses. A slightly smaller or larger value would have led to a dramatically different universe. Here, we show that this difference results from the competition between electromagnetic and mass isospin breaking effects. We performed lattice quantum-chromodynamics and quantum-electrodynamics computations with four nondegenerate Wilson fermion flavors and computed the neutron-proton mass-splitting with an accuracy of $300$ kilo-electron volts, which is greater than $0$ by $5$ standard deviations. We also determine the splittings in the $\Sigma$, $\Xi$, $D$ and $\Xi_{cc}$ isospin multiplets, exceeding in some cases the precision of experimental measurements.Comment: 57 pages, 15 figures, 6 tables, revised versio